Sign In
Buy LXRX
$2.31
-0.0300 (-1.28%)
At Close: Jul 31, 2026
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Thursday, 01'st Aug 2024
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
08:49am, Tuesday, 30'th Jul 2024
Penny stocks represent an interesting investment opportunity.
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
08:00am, Thursday, 25'th Jul 2024
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the market
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
12:17pm, Wednesday, 17'th Jul 2024
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
09:15am, Monday, 08'th Jul 2024
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief exec
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
09:25am, Friday, 21'st Jun 2024
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
08:00am, Friday, 21'st Jun 2024
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sess
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
08:00am, Wednesday, 29'th May 2024
NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pha
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
07:30am, Wednesday, 29'th May 2024
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon'
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
07:30am, Thursday, 09'th May 2024
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript
05:14am, Sunday, 05'th May 2024
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Lisa DeFrancesco - Head of Investor Relations and Strategy Lonnel Coats - Chie
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
07:11pm, Thursday, 02'nd May 2024
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago.
